Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22543799 | 0.84 | HSD17B10 (0.39) | HRH4HSD17B10SQORKDM4E | |
| SCHEMBL25530094 | 0.78 | HRH4 (0.35) | HRH4HSD17B10SQORGABRA2GABRB2 | |
| SCHEMBL10220676 | 0.77 | HRH4 (0.37) | HRH4HSD17B10CYP3A4TSHRMAPT | |
| SCHEMBL24966591 | 0.76 | HSP90AA1 (0.41) | HSD17B10SQORADORA2AADORA1CYP3A4 | |
| SCHEMBL23920002 | 0.76 | HRH4 (0.40) | HRH4HSD17B10CYP3A4TSHRGABRA2 | |
| SCHEMBL25928607 | 0.76 | KDM4E (0.38) | HSD17B10SQORADORA2AADORA1MEN1 | |
| SCHEMBL23872483 | 0.76 | HRH4 (0.36) | HRH4HSD17B10CYP3A4TSHRKMT2A | |
| SCHEMBL28783722 | 0.75 | — | — | |
| SCHEMBL15927343 | 0.75 | GABRA2 (0.49) | HRH4GABRA2GABRB2 | |
| SCHEMBL22549257 | 0.74 | HSD17B10 (0.41) | HRH4HSD17B10SQORKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002361-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002361-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK3, IRAK2 | HRH4 194/4885HSD17B10 2534/4885SQOR 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.